‹ ›
MYP_085573
← PREVIOUS NEXT → BACK
Basic Information
C8- N27
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
27 amino acids
C136H235N45O40
Standard
Sequence
RQLLSGIVQQQNNLLRAIEAQQHLLQK
Physicochemical Analysis
3140.60 Da
10.84
1.85
1.59
0.0685
-0.47
0.57
-0.13
67.36
133.70
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1443.76
-15.21
47.0
43.0
113.0
221.0
1.0
35.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0125955 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
C8(octanoic acid)
None
C8(octanoic acid)
Bio-Activity Profile
Antiviral Fusion inhibition
inhibition of peptide against virus-cell fusion on CD4-expressing cells
0.293±0.027 μM
IC50
Mammalian: 1 h; Yeast: 2 min; E. coli: 2 min
PaperVirus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. | Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y. | FASEB J. 2010 Nov;24(11):4196-202. | DOI:10.1096/fj.09-151704 | PMID:20605950 PMID20605950 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20605950/
RECORD: Rec_0195919 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
C16(hexadecanoic acid)
None
Bio-Activity Profile
Antimicrobial Antiviral
inhibition of peptide against virus-cell fusion on CD4-expressing cells
0.01±0.001 μM
IC50
PMID20605950 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20605950/
RECORD: Rec_0203562 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
C8(octanoic acid)
None
C8(octanoic acid)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 | against cell; -cell; HXBc2 cells
1.075±0.09 μM
IC50
Mammalian: 1 h; Yeast: 2 min; E. coli: 2 min
PaperVirus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. | Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y. | FASEB J. 2010 Nov;24(11):4196-202. | DOI:10.1096/fj.09-151704 | PMID:20605950 PMID20605950 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20605950/
RECORD: Rec_0207666 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Gaegurin
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1
PMID20605950 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20605950/
RECORD: Rec_0229367 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
C12(dodecanoic acid)
None
C12(dodecanoic acid)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 | against cell; -cell; HXBc2 cells
0.473±0.074 μM
IC50
Mammalian: 1 h; Yeast: 2 min; E. coli: 2 min
PaperVirus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. | Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y. | FASEB J. 2010 Nov;24(11):4196-202. | DOI:10.1096/fj.09-151704 | PMID:20605950 PMID20605950 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20605950/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 2 of 4